Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of infections in association with severe lymphopenia

被引：0
|
作者：
Cook, S. [1 ]
Leist, T. [2 ]
Comi, G. [3 ,4 ]
Montalban, X. [5 ]
Sylvester, E. [6 ]
Hicking, C. [6 ]
Dangond, F. [7 ]
机构：
[1] Rutgers State Univ, New Jersey Med Sch, Newark, NJ 07102 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Div Clin Neuroimmunol, Philadelphia, PA 19107 USA
[3] Univ Vita Salute San Raffaele, Osped San Raffaele, Dept Neurol, Milan, Italy
[4] Univ Vita Salute San Raffaele, Osped San Raffaele, Inst Expt Neurol, Milan, Italy
[5] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Barcelona, Spain
[6] Merck KGaA, Darmstadt, Germany
[7] EMD Serono Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P635
引用
收藏
页码：299 / 300
页数：2
相关论文
共 50 条
  • [1] Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
    Giovannoni, Gavin
    Coyle, Patricia K.
    Vermersch, Patrick
    Walker, Bryan
    Aldridge, Julie
    Nolting, Axel
    Galazka, Andrew
    Lemieux, Caroline
    Leist, Thomas P.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [2] Incidence of infections and severe lymphopenia in patients newly initiating cladribine tablets or fingolimod for treatment of multiple sclerosis: CLARION study
    Hillert, J.
    Butzkueven, H.
    Soilu-Hanninen, M.
    Ziemssen, T.
    Kuhle, J.
    Berger, J. R.
    Aydemir, A.
    Sonajalg, J.
    Bezemer, I.
    Sabido, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 639 - 640
  • [3] Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Giovannoni, Gavin
    Nolting, Axel
    Hicking, Christine
    Galazka, Andrew
    Sylvester, Elke
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 : 157 - 167
  • [4] Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of safety from the multiple sclerosis clinical development program
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Sylvester, E.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 305 - 306
  • [5] Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
    Cook, Stuart D.
    Giovannoni, Gavin
    Leist, Thomas P.
    Syed, Sana
    Nolting, Axel
    Damian, Doris
    Schick, Regina
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 54 - 55
  • [6] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, Stuart
    Giovannoni, Gavin
    Leist, Thomas
    Syed, Sana
    Nolting, Axel
    Damian, Doris
    Schick, Regina
    NEUROLOGY, 2019, 92 (15)
  • [7] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, S.
    Giovannoni, G.
    Leist, T.
    Syed, S.
    Nolting, A.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 465 - 466
  • [8] Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
    Cook, S.
    Giovannoni, G.
    Leist, T.
    King, J.
    Syed, S.
    Nolting, A.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 469 - 469
  • [9] Cladribine Tablets' Potential in Multiple Sclerosis Treatment
    Costello, Kathleen
    Sipe, Jack C.
    JOURNAL OF NEUROSCIENCE NURSING, 2008, 40 (05) : 275 - 280
  • [10] Analysis of Infection in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets who had Grade ≥3 Lymphopenia
    Coyle, P. K.
    Giovannoni, G.
    Vermersch, P.
    Walker, B.
    Aldridge, J.
    Nolting, A.
    Galazka, A.
    Lemieux, C.
    Leist, T. P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 48 - 48
12345